Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 5/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.46 |
| ▸ | CBFB | Q13951 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7172514 | 0.90 | PDE4A (0.60) | PDE4AKCNH2L3MBTL1LMNA | |
| SCHEMBL7172524 | 0.87 | KCNH2 (0.53) | PDE4AKCNH2L3MBTL1 | |
| SCHEMBL7171214 | 0.85 | KCNH2 (0.54) | PDE4AKCNH2KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL7173411 | 0.85 | PDE4A (0.49) | PDE4AKCNH2 | |
| SCHEMBL7688432 | 0.85 | PDE4A (0.55) | PDE4AKCNH2LMNA | |
| SCHEMBL7169759 | 0.84 | PDE4A (0.62) | PDE4AKCNH2 | |
| SCHEMBL7172789 | 0.83 | PDE4A (0.57) | PDE4AKCNH2NPC1RAB9AHSD17B10 | |
| SCHEMBL7167992 | 0.83 | PDE4A (0.53) | PDE4AKCNH2 | |
| SCHEMBL7171340 | 0.83 | PDE4A (0.71) | PDE4AKCNH2 | |
| SCHEMBL7167745 | 0.83 | PDE4A (0.53) | PDE4AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541480-B2 | Controlling cytokines | SUNTORY LIMITED (JP) | 2003-04-01 | — | — | US | disclosed |
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6297248-B1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | SUNTORY LIMITED (JP) | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | PDE3A, PDE5A, PDE3B | PDE4A 4/4885KCNH2 559/4885ALDH1A1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.